Tian Yuan assisted Nanjing IMPACT Therapeutics Co., Ltd. ("IMPACT Therapeutics" or the "Company") in successfully listing on the Main Board of the Hong Kong Stock Exchange on May 13, 2026, under stock code 7630.HK. Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited acted as the joint sponsors for this offering and listing project. IMPACT Therapeutics' Hong Kong offering received an enthusiastic market response, successfully introducing cornerstone investors including Nanjing Biomedical Valley Construction and Development Co., Ltd. (BPV), Huatai Capital Investment (for Huatai back-to-back TRS and Huatai client TRS), Tencent Holdings Limited, LAV entities, Ruiguan, WWHCP, and First Quarter Moon OFC—Phecda Fund. Its Hong Kong public offering was oversubscribed by 2,282.4 times.

Founded in 2009, IMPACT Therapeutics is a commercial-stage, innovation-driven biotech company dedicated to advancing precision cancer therapies globally based on the mechanism of synthetic lethality, aiming to develop innovative therapies to address unmet medical needs of cancer patients. The company possesses one self-developed core product and 11 self-developed drug candidates. Its core product, Senaparib, has already been commercialized in China as a first-line (1L) maintenance therapy for ovarian cancer applicable to the all-comer population (regardless of mutation status). The company is also currently one of only three companies globally to possess both a commercial-stage PARP1/2 inhibitor and a clinical-stage next-generation PARP1 selective inhibitor.

In this Hong Kong Main Board listing project for IMPACT Therapeutics, Tian Yuan acted as the PRC legal advisor to the joint sponsors, deeply involved throughout the entire listing process. The firm provided comprehensive, high-quality, and efficient legal services throughout the offering and listing, demonstrating Tian Yuan's extensive experience and professionalism in the offshore capital markets, particularly its strong capabilities and industry-leading position in specialized sectors such as 18A biotech. This earned high recognition and unanimous praise from the company, the joint sponsors, and all parties involved.

This project was led by Tian Yuan senior partners Xu Ying and Gao Xiang, with support from partner Cen Yingqi, and associates Cheng Jiajia, Cui Taiyuan, Zhang Dawei, and Li Shuqing.